Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer
Abstract Modulating macrophages presents a promising avenue in tumor immunotherapy. However, tumor cells have evolved mechanisms to evade macrophage activation and phagocytosis. Herein, we introduced a bispecific antibody-based nanoengager to facilitate the recognition and phagocytosis of tumor cells by macrophages. Specifically, we genetically engineered two single chain variable fragments (scFv) onto cell membrane: anti-CD40 scFv for engaging with macrophages and anti-Claudin18.2 (CLDN18.2) scFv for interacting with tumor cells. These nanoengagers were further constructed by coating scFv-anchored membrane into PLGA nanoparticle core. Our developed nanoengagers significantly boosted immune responses, including increased recognition and phagocytosis of tumor cells by macrophages, enhanced activation and antigen presentation, and elevated cytotoxic T lymphocyte activity. These combined benefits resulted in enhancing antitumor efficacy against highly aggressive “cold” pancreatic cancer. Overall, this study offers a versatile nanoengager design for immunotherapy, achieved through genetically engineering to incorporate antibody-anchored membrane..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Journal of nanobiotechnology - 22(2024), 1 vom: 11. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Haoqi [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12951-024-02369-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055106218 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055106218 | ||
| 003 | DE-627 | ||
| 005 | 20240312064728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12951-024-02369-9 |2 doi | |
| 035 | |a (DE-627)SPR055106218 | ||
| 035 | |a (SPR)s12951-024-02369-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 610 |q VZ |
| 084 | |a 58.30 |2 bkl | ||
| 084 | |a 50.94 |2 bkl | ||
| 100 | 1 | |a Zhang, Haoqi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Abstract Modulating macrophages presents a promising avenue in tumor immunotherapy. However, tumor cells have evolved mechanisms to evade macrophage activation and phagocytosis. Herein, we introduced a bispecific antibody-based nanoengager to facilitate the recognition and phagocytosis of tumor cells by macrophages. Specifically, we genetically engineered two single chain variable fragments (scFv) onto cell membrane: anti-CD40 scFv for engaging with macrophages and anti-Claudin18.2 (CLDN18.2) scFv for interacting with tumor cells. These nanoengagers were further constructed by coating scFv-anchored membrane into PLGA nanoparticle core. Our developed nanoengagers significantly boosted immune responses, including increased recognition and phagocytosis of tumor cells by macrophages, enhanced activation and antigen presentation, and elevated cytotoxic T lymphocyte activity. These combined benefits resulted in enhancing antitumor efficacy against highly aggressive “cold” pancreatic cancer. Overall, this study offers a versatile nanoengager design for immunotherapy, achieved through genetically engineering to incorporate antibody-anchored membrane. | ||
| 650 | 4 | |a Nanoengagers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Macrophages |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cell membrane |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pancreatic cancer |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Li, Yuanke |4 aut | |
| 700 | 1 | |a Kang, Helong |4 aut | |
| 700 | 1 | |a Lan, Jingping |4 aut | |
| 700 | 1 | |a Hou, Lin |4 aut | |
| 700 | 1 | |a Chen, Zhengbang |4 aut | |
| 700 | 1 | |a Li, Fan |4 aut | |
| 700 | 1 | |a Liu, Yanqin |4 aut | |
| 700 | 1 | |a Zhao, Jiliang |4 aut | |
| 700 | 1 | |a Li, Na |4 aut | |
| 700 | 1 | |a Wan, Yajuan |4 aut | |
| 700 | 1 | |a Zhu, Yiping |4 aut | |
| 700 | 1 | |a Zhao, Zhen |4 aut | |
| 700 | 1 | |a Zhang, Hongkai |4 aut | |
| 700 | 1 | |a Zhuang, Jie |4 aut | |
| 700 | 1 | |a Huang, Xinglu |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nanobiotechnology |d BioMed Central, 2003 |g 22(2024), 1 vom: 11. März |w (DE-627)SPR02945347X |w (DE-600)2100022-0 |x 1477-3155 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:1 |g day:11 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12951-024-02369-9 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 58.30 |q VZ |
| 936 | b | k | |a 50.94 |q VZ |
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 1 |b 11 |c 03 | ||